menu
    • menu

    Company profile for Brooklyn ImmunoTherapeutics

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company committed to developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocy...
    Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company committed to developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. Based on the encouraging results of the Phase 2a clinical trial, Brooklyn ImmunoTherapeutics initiated a Phase 2b clinical trial.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Brooklyn ImmunoTherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1040 First Ave. # 361 New York, NY 10022 (212) 582-1199
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://brooklynitx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Brooklyn ImmunoTherapeutics Announces Name Change to Eterna
    Brooklyn ImmunoTherapeutics Announces Name Change to Eterna

    11 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/11/2531832/0/en/Brooklyn-ImmunoTherapeutics-Announces-Name-Change-to-Eterna-Therapeutics-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    11 Oct 2022
    Share Share
    Brooklyn's immunotherapy flops phase 2 in oral cavity cancer
    Brooklyn's immunotherapy flops phase 2 in oral cavity cancer

    28 Jul 2022

    // Annalee Armstrong FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/brooklyn-hails-immunotherapy-achieving-primary-objective-just-not-primary-endpoint

    Annalee Armstrong FIERCEBIOTECH
    28 Jul 2022
    Share Share
    Brooklyn ImmunoTherapeutics Announces Results of PII Study of IRX-2
    Brooklyn ImmunoTherapeutics Announces Results of PII Study of IRX-2

    26 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/26/2485793/0/en/Brooklyn-ImmunoTherapeutics-Announces-Results-of-Phase-2-Study-of-IRX-2-in-Head-and-Neck-Cancer.html

    GLOBENEWSWIRE
    26 Jul 2022
    Share Share
    Brooklyn Immuno Announces Receipt of Nasdaq Notification
    Brooklyn Immuno Announces Receipt of Nasdaq Notification

    17 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/17/2464932/0/en/Brooklyn-ImmunoTherapeutics-Announces-Receipt-of-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html

    GLOBENEWSWIRE
    17 Jun 2022
    Share Share
    Brooklyn ImmunoTherapeutics Announces Board Changes
    Brooklyn ImmunoTherapeutics Announces Board Changes

    07 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/07/2457573/0/en/Brooklyn-ImmunoTherapeutics-Announces-Board-Changes.html

    GLOBENEWSWIRE
    07 Jun 2022
    Share Share
    Brooklyn ImmunoTherapeutics Announces Changes to Executive Management
    Brooklyn ImmunoTherapeutics Announces Changes to Executive Management

    31 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/31/2453125/0/en/Brooklyn-ImmunoTherapeutics-Announces-Changes-to-Executive-Management-Matt-Angel-Ph-D-Appointed-Interim-Chief-Executive-Officer-and-President-Andrew-Jackson-Appointed-Chief-Financi.html

    GLOBENEWSWIRE
    31 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search